Gue M, Junien J L, Del Rio C, Bueno L
Department of Pharmacology, Institut National de la Recherche Agronomique, Toulouse, France.
J Pharmacol Exp Ther. 1992 Jun;261(3):850-5.
The effects of neuropeptide Y (NPY), sigma ligand (JO 1784) and sulfated cholecystokinin octapeptide (CCK8s) on emotional stress (ES) and corticotropin-releasing hormone (CRH)-induced colonic hypermotility were evaluated in rats equipped with chronically implanted electrodes on the colon and a small catheter into the lateral ventricle of the brain. A 139% (97-172%) increase in colonic spike burst frequency was observed in rats placed in a test cage in which they had previously received electric footshocks, an event assimilated to an ES. Intracerebroventricular injection of CRH (0.5 microgram/kg) mimicked the effects of ES by increasing colonic spike burst frequency by 89.0%. Given i.c.v., both JO 1784 (0.1 microgram/kg) and NPY (0.15 microgram/kg) blocked these stimulatory effects. Similarly, i.c.v. administration of CCK8s (0.1 microgram/kg) abolished both ES and CRH stimulated colonic motility, an effect reproduced by central injection of JMV 180, a cholecystokinin (CCK) derivative with high affinity for CCKA receptors, (1 microgram/kg), but not by JMV 170, a CCK derivative with low affinity for CCKA receptor at similar or higher dose. BMY 14802 (a sigma receptor antagonist) injected s.c. (1 mg/kg) abolished the antagonistic effects of JO 1784 and NPY on the ES-induced colonic hyperkinesia. Injected i.c.v., devazepide (L 364,718), a CCKA receptor antagonist, at 0.1 and 1 microgram/kg, abolished the effect of both JO 1784 and NPY; by contrast L365,260, a CCKB antagonist, required a dose of 10 micrograms/kg to block the antagonistic effect of NPY and JO 1784.(ABSTRACT TRUNCATED AT 250 WORDS)
在结肠上长期植入电极并在脑侧脑室插入一根小导管的大鼠中,评估了神经肽Y(NPY)、西格玛配体(JO 1784)和硫酸化胆囊收缩素八肽(CCK8s)对情绪应激(ES)和促肾上腺皮质激素释放激素(CRH)诱导的结肠运动亢进的影响。在放置于曾接受过电击足底的测试笼中的大鼠中,观察到结肠棘波爆发频率增加了139%(97 - 172%),这一事件被视为一种ES。脑室内注射CRH(0.5微克/千克)通过使结肠棘波爆发频率增加89.0%来模拟ES的作用。脑室内给予JO 1784(0.1微克/千克)和NPY(0.15微克/千克)均可阻断这些刺激作用。同样,脑室内给予CCK8s(0.1微克/千克)可消除ES和CRH刺激的结肠运动,脑室内注射对CCKA受体具有高亲和力的胆囊收缩素(CCK)衍生物JMV 180(1微克/千克)可重现这一效应,但对CCKA受体具有低亲和力的CCK衍生物JMV 170在相似或更高剂量时则不能。皮下注射BMY 14802(一种西格玛受体拮抗剂,1毫克/千克)可消除JO 1784和NPY对ES诱导的结肠运动亢进的拮抗作用。脑室内注射CCKA受体拮抗剂地伐西匹(L 364,718),剂量为0.1和1微克/千克时,可消除JO 1784和NPY的作用;相比之下,CCKB拮抗剂L365,260需要10微克/千克的剂量才能阻断NPY和JO 1784的拮抗作用。(摘要截选至250字)